Safety of enoxaparin versus unfractionated heparin during percutaneous coronary intervention

Texas Heart Institute Journal

Volumn 36, Issue 2, 2009, Pages 98-103

  Díez, José G ^a,b   Medina, Hector M ^a   Cheong, Benjamin Y C ^a,b   O'Meallie, Lawrence ^c   Ferguson, James J ^a,b  

^a ST LUKE S EPISCOPAL HOSPITAL   (United States)

^b BAYLOR COLLEGE OF MEDICINE   (United States)

^c TULANE UNIVERSITY HEALTH SCIENCES CENTER   (United States)

Author keywords

Angioplasty, transluminal, percutanous coronary; Anticoagulants; Catheterization; Enoxaparin therapeutic use; Heparin, low molecular weight; Heparin, unfractionated; Heparin therapeutic use; Treatment outcome

Indexed keywords

ACETYLSALICYLIC ACID; ANTICOAGULANT AGENT; CLOPIDOGREL; ENOXAPARIN; EPTIFIBATIDE; HEPARIN; TROPONIN I;

ADULT; ARTICLE; BLEEDING; CONTROLLED STUDY; DRUG EFFICACY; DRUG SAFETY; EMERGENCY WARD; FEMALE; HEART MUSCLE INJURY; HUMAN; MAJOR CLINICAL STUDY; MALE; PERCUTANEOUS CORONARY INTERVENTION; SIDE EFFECT; THROMBOCYTE COUNT;

ADMINISTRATION, ORAL; ANGIOPLASTY, TRANSLUMINAL, PERCUTANEOUS CORONARY; ANTICOAGULANTS; BIOLOGICAL MARKERS; ENOXAPARIN; FEMALE; FIBRINOLYTIC AGENTS; HEMOGLOBINS; HEMORRHAGE; HEPARIN; HUMANS; INJECTIONS, INTRAVENOUS; INJECTIONS, SUBCUTANEOUS; LOGISTIC MODELS; MALE; MIDDLE AGED; ODDS RATIO; PEPTIDES; PLATELET AGGREGATION INHIBITORS; PLATELET COUNT; RISK ASSESSMENT; STENTS; THROMBOSIS; TREATMENT OUTCOME; TROPONIN I;

EID: 66149093462     PISSN: 07302347     EISSN: 15266702     Source Type: Journal    
DOI: None     Document Type: Article

References (36)

1. Xiao Z, Theroux P. Platelet activation with unfractionated heparin at therapeutic concentrations and comparisons with a low-molecular-weight heparin and with a direct thrombin inhibitor. Circulation 1998;97(3):251-256
2. Hirsh J, Warkentin TE, Raschke R, Granger C, Ohman EM, Dalen JE. Heparin and low-molecular-weight heparin: mechanisms of action, pharmacokinetics, dosing considerations, monitoring, efficacy, and safety [published erratum appears in Chest 1999;115(6):1760]. Chest 1998;114(5 Suppl):489S-510S.
3. Goodman SG, Fitchett D, Armstrong PW, Tan M, Langer A; Integrilin and Enoxaparin Randomized Assessment of Acute Coronary Syndrome Treatment (INTERACT) Trial Investigators. Randomized evaluation of the safety and efficacy of enoxaparin versus unfractionated heparin in high-risk patients with non-ST-segment elevation acute coronary syndromes receiving the glycoprotein IIb/IIIa inhibitor eptifibatide. Circulation 2003;107(2):238-244
4. Anand SS, Yusuf S, Pogue J, Ginsberg JS, Hirsh J; Organization to Assess Strategies for Ischemic Syndromes Investigators. Relationship of activated partial thromboplastin time to coronary events and bleeding in patients with acute coronary syndromes who receive heparin. Circulation 2003;107(23):2884-2888
5. Montalescot G, Philippe F, Ankri A, Vicaut E, Bearez E, Poulard JE, et al. Early increase of von Willebrand factor predicts adverse outcome in unstable coronary artery disease: beneficial effects of enoxaparin. French Investigators of the ESSENCE Trial. Circulation 1998;98(4):294-299
6. Cohen M, Demers C, Gurfinkel EP, Turpie AG, Fromell GJ, Goodman S, et al. A comparison of low-molecular-weight heparin with unfractionated heparin for unstable coronary artery disease. Efficacy and Safety of Subcutaneous Enoxaparin in Non-Q-Wave Coronary Events Study Group. N Engl J Med 1997;337(7):447-452
7. Antman EM, McCabe CH, Gurfinkel EP, Turpie AG, Bernink PJ, Salein D, et al. Enoxaparin prevents death and cardiac ischemic events in unstable angina/non-Q-wave myocardial infarction. Results of the thrombolysis in myocardial infarction (TIMI) 11B trial. Circulation 1999;100(15):1593-1601
8. Antman EM, Cohen M, Radley D, McCabe C, Rush J, Premmereur J, Braunwald E. Assessment of the treatment effect of enoxaparin for unstable angina/non-Q-wave myocardial infarction. TIMI 11B-ESSENCE meta-analysis. Circulation 1999;100(15):1602-1608
9. Anderson JL, Adams CD, Antman EM, Bridges CR, Califf RM, Casey DE Jr, et al. ACC/AHA 2007 guidelines for the management of patients with unstable angina/non-ST-elevation myocardial infarction: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to Revise the 2002 Guidelines for the Management of Patients with Unstable Angina/Non-ST-Elevation Myocardial Infarction) developed in collaboration with the American College of Emergency Physicians, the Society for Cardiovascular Angiography and Interventions, and the Society of Thoracic Surgeons endorsed by the American Association of Cardiovascular and Pulmonary Rehabilitation and the Society for Academic Emergency Medicine [published erratum appears in J Am Coll Cardiol 2008;51(9):974]. J Am Coll Cardiol 2007;50(7):e1-e157.
10. Cannon CP, Weintraub WS, Demopoulos LA, Vicari R, Frey MJ, Lakkis N, et al. Comparison of early invasive and conservative strategies in patients with unstable coronary syndromes treated with the glycoprotein IIb/IIIa inhibitor tirofiban. N Engl J Med 2001;344(25):1879-1887.
11. Neumann FJ, Kastrati A, Pogatsa-Murray G, Mehilli J, Bollwein H, Bestehorn HP, et al. Evaluation of prolonged antithrombotic pretreatment ("cooling-off" strategy) before intervention in patients with unstable coronary syndromes: a randomized controlled trial. JAMA 2003;290(12):1593-1599
12. Bavry AA, Kumbhani DJ, Rassi AN, Bhatt DL, Askari AT. Benefit of early invasive therapy in acute coronary syndromes: a meta-analysis of contemporary randomized clinical trials. J Am Coll Cardiol 2006;48(7):1319-1325
13. Fox KA, Poole-Wilson PA, Henderson RA, Clayton TC, Chamberlain DA, Shaw TR, et al. Interventional versus conservative treatment for patients with unstable angina or non-ST-elevation myocardial infarction: the British Heart Foundation RITA 3 randomised trial. Randomized Intervention Trial of unstable Angina. Lancet 2002;360(9335):743-751
14. Kereiakes DJ, Fry E, Matthai W, Niederman A, Barr L, Brodie B, et al. Combination enoxaparin and abciximab therapy during percutaneous coronary intervention: "NICE guys finish first". J Invasive Cardiol 2000;12 Suppl A:1A-5A.
15. Young JJ, Kereiakes DJ, Grines CL. Low-molecular-weight heparin therapy in percutaneous coronary intervention: the NICE 1 and NICE 4 trials. National Investigators Collaborating on Enoxaparin Investigators. J Invasive Cardiol 2000;12 Suppl E:E14-8.
16. Bhatt DL, Lee BI, Casterella PJ, Pulsipher M, Rogers M, Cohen M, et al. Safety of concomitant therapy with eptifibatide and enoxaparin in patients undergoing percutaneous coronary intervention: results of the Coronary Revascularization Using Integrilin and Single bolus Enoxaparin Study. J Am Coll Cardiol 2003;41(1):20-25
17. Stone GW, Moses JW, Leon MB. Left main drug-eluting stents: natural progression or a bridge too far? J Am Coll Cardiol 2007;50(6):498-500.
18. Díez JG, Lievano MJ, Croitoru M, Olaya CA, Ferguson JJ. Enoxaparin anticoagulation for percutaneous coronary interventions: a pilot safety study [abstract]. Circulation 1999 Suppl 1;100(18):I-188.
19. Nguyen VD, O'Meallie L, Tenaglia A, Diez JG. Low molecular weight heparin versus unfractionated heparin in percutaneous coronary intervention: the Tulane experience [abstract]. Catheter Cardiovasc Interv 2002;56(1):124.
20. Weitz JI. Low-molecular-weight heparins [published erratum appears in N Engl J Med 1997;337(21):1567]. N Engl J Med 1997;337(10):688-698
21. Moliterno DJ, Hermiller JB, Kereiakes DJ, Yow E, Applegate RJ, Braden GA, et al. A novel point-of-care enoxaparin monitor for use during percutaneous coronary intervention. Results of the Evaluating Enoxaparin Clotting Times (ELECT) Study. J Am Coll Cardiol 2003;42(6):1132-1139
22. Diez JG, Cheong BY, O'Meallie LP, Alt EU. Monitoring of enoxaparin level using citrated clotting time during percutaneous coronary intervention. J Interv Cardiol 2004;17(5):307-313
23. Collet JP, Montalescot G, Lison L, Choussat R, Ankri A, Drobinski G, et al. Percutaneous coronary intervention after subcutaneous enoxaparin pretreatment in patients with unstable angina pectoris. Circulation 2001;103(5):658-663
24. Choussat R, Montalescot G, Collet JP, Vicaut E, Ankri A, Gallois V, et al. A unique, low dose of intravenous enoxaparin in elective percutaneous coronary intervention. J Am Coll Cardiol 2002;40(11):1943-1950.
25. Martin JL, Fry ET, Sanderink GJ, Atherley TH, Guimart CM, Chevalier PJ, et al. Reliable anticoagulation with enoxaparin in patients undergoing percutaneous coronary intervention: the pharmacokinetics of enoxaparin in PCI (PEPCI) study. Catheter Cardiovasc Interv 2004;61(2):163-170
26. Aslam MS, Sundberg S, Sabri MN, Cooke D, Lakier JB. Pharmacokinetics of intravenous/subcutaneous Enoxaparin in patients with acute coronary syndrome undergoing percutaneous coronary interventions. Catheter Cardiovasc Interv 2002;57(2):187-190
27. Win HK, Caldera AE, Maresh K, Lopez J, Rihal CS, Parikh MA, et al. Clinical outcomes and stent thrombosis following off-label use of drug-eluting stents. JAMA 2007;297(18):2001-2009.
28. Platelet glycoprotein IIb/IIIa receptor blockade and low-dose heparin during percutaneous coronary revascularization. The EPILOG Investigators. N Engl J Med 1997;336(24):1689-1696
29. Randomised placebo-controlled and balloon-angioplasty-controlled trial to assess safety of coronary stenting with use of platelet glycoprotein-IIb/IIIa blockade. Lancet 1998;352(9122):87-92.
30. Carnendran L, Borkowski R, Markabawi B, Warner MF. Safety and efficacy of low-dose intravenous enoxaparin and GP IIb/IIIa inhibitor therapy during PCI. J Invasive Cardiol 2003;15(5):235-238
31. Montalescot G, White HD, Gallo R, Cohen M, Steg PG, Aylward PE, et al. Enoxaparin versus unfractionated heparin in elective percutaneous coronary intervention. N Engl J Med 2006;355(10):1006-1017
32. Ferguson JJ, Califf RM, Antman EM, Cohen M, Grines CL, Goodman S, et al. Enoxaparin vs unfractionated heparin in high-risk patients with non-ST-segment elevation acute coronary syndromes managed with an intended early invasive strategy: primary results of the SYNERGY randomized trial. JAMA 2004;292(1):45-54.
33. Kizer JR, Muttrej MR, Matthai WH, McConnell J, Nardone H, Sonel AF, et al. Role of cardiac troponin T in the long-term risk stratification of patients undergoing percutaneous coronary intervention. Eur Heart J 2003;24(14):1314-1322
34. Ohlmann P, Monassier JP, Michotey MO, Berenger N, Jacquemin L, Laval G, et al. Troponin I concentrations following primary percutaneous coronary intervention predict large infarct size and left ventricular dysfunction in patients with ST-segment elevation acute myocardial infarction. Atherosclerosis 2003;168(1):181-189
35. Ricciardi MJ, Davidson CJ, Gubernikoff G, Beohar N, Eckman LJ, Parker MA, Bonow RO. Troponin I elevation and cardiac events after percutaneous coronary intervention. Am Heart J 2003;145(3):522-528
36. Cantor WJ, Newby LK, Christenson RH, Tuttle RH, Hasselblad V, Armstrong PW, et al. Prognostic significance of elevated troponin I after percutaneous coronary intervention. J Am Coll Cardiol 2002;39(11):1738-1744